WO2007085497A8 - Markers for the prediction of outcome of anthracycline treatment - Google Patents

Markers for the prediction of outcome of anthracycline treatment

Info

Publication number
WO2007085497A8
WO2007085497A8 PCT/EP2007/000796 EP2007000796W WO2007085497A8 WO 2007085497 A8 WO2007085497 A8 WO 2007085497A8 EP 2007000796 W EP2007000796 W EP 2007000796W WO 2007085497 A8 WO2007085497 A8 WO 2007085497A8
Authority
WO
WIPO (PCT)
Prior art keywords
outcome
markers
prediction
treatment
anthracycline treatment
Prior art date
Application number
PCT/EP2007/000796
Other languages
French (fr)
Other versions
WO2007085497A3 (en
WO2007085497A2 (en
Inventor
John Foekens
John Martens
Serenella Eppenberger-Scastori
Vincent Vuaroqueaux
Frederique Spyratos
Nadia Harbeck
Manfred Schmitt
Heinz Hoefler
Sabine Maier
Gunter Weiss
Ralf Lesche
Thomas Hildmann
Achim Plum
Olivier Hartmann
Anne Fassbender
Dimo Dietrich
Original Assignee
Epigenomics Ag
John Foekens
John Martens
Serenella Eppenberger-Scastori
Vincent Vuaroqueaux
Frederique Spyratos
Nadia Harbeck
Manfred Schmitt
Heinz Hoefler
Sabine Maier
Gunter Weiss
Ralf Lesche
Thomas Hildmann
Achim Plum
Olivier Hartmann
Anne Fassbender
Dimo Dietrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigenomics Ag, John Foekens, John Martens, Serenella Eppenberger-Scastori, Vincent Vuaroqueaux, Frederique Spyratos, Nadia Harbeck, Manfred Schmitt, Heinz Hoefler, Sabine Maier, Gunter Weiss, Ralf Lesche, Thomas Hildmann, Achim Plum, Olivier Hartmann, Anne Fassbender, Dimo Dietrich filed Critical Epigenomics Ag
Publication of WO2007085497A2 publication Critical patent/WO2007085497A2/en
Publication of WO2007085497A8 publication Critical patent/WO2007085497A8/en
Publication of WO2007085497A3 publication Critical patent/WO2007085497A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Abstract

The present invention relates to methods for prognosis and/or predicting outcome of treatment with anthracycline treatment of cell proliferative disorder patients. This is achieved by determining the expression level of at least one gene selected from the group consisting of the genes according to Table 1. The invention also relates to sequences, oligonucleotides and antibodies which can be used within the described methods.
PCT/EP2007/000796 2006-01-30 2007-01-30 Markers for the prediction of outcome of anthracycline treatment WO2007085497A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP06090015.6 2006-01-30
EP06090015 2006-01-30
EP06090050.3 2006-04-07
EP06090050 2006-04-07
EP06090081.8 2006-05-18
EP06090081 2006-05-18
EP06124780.5 2006-11-24
EP06124780 2006-11-24

Publications (3)

Publication Number Publication Date
WO2007085497A2 WO2007085497A2 (en) 2007-08-02
WO2007085497A8 true WO2007085497A8 (en) 2007-10-25
WO2007085497A3 WO2007085497A3 (en) 2007-12-06

Family

ID=38042807

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/000796 WO2007085497A2 (en) 2006-01-30 2007-01-30 Markers for the prediction of outcome of anthracycline treatment

Country Status (1)

Country Link
WO (1) WO2007085497A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108367995A (en) * 2015-10-06 2018-08-03 安大略省癌症研究所 Histone approach is targeted to detect and overcome anthracycline resistant

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078098A2 (en) * 2006-11-01 2009-07-15 Epigenomics AG Methods, systems and computer program products for determining treatment response biomarkers
US20100075334A1 (en) * 2007-04-16 2010-03-25 Yong Sung Kim Methylation biomarker for early detection of gastric cancer
CA2694703A1 (en) * 2007-08-16 2009-02-26 Aventis Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
EP2302069A1 (en) * 2007-12-11 2011-03-30 Epigenomics AG Methods and nucleic acids for analyses of cell proliferative disorders
EP2641978A1 (en) * 2008-05-12 2013-09-25 Genomic Health, Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
ES2606703T3 (en) 2008-07-15 2017-03-27 Epigenomics Ag Method to predict the prognosis of a breast cancer therapy based on gene methylation analysis
WO2011109637A1 (en) * 2010-03-03 2011-09-09 Koo Foundation Sun Yat-Sen Cancer Center Methods for classifying and treating breast cancers
US9458460B2 (en) 2011-06-29 2016-10-04 National University Of Singapore Pharmaceutical compositions for treating cancer
CA2840149C (en) 2011-07-08 2021-10-26 Epigenomics Ag Methods and nucleic acids for determining the prognosis of a cancer subject
WO2016008048A1 (en) * 2014-07-15 2016-01-21 Ontario Institute For Cancer Research Methods and devices for predicting anthracycline treatment efficacy
EP3246413A1 (en) * 2016-05-20 2017-11-22 Klinikum rechts der Isar der Technischen Universität München A method for predicting a breast cancer patient's response to anthracycline treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2527285A1 (en) * 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP1692316A2 (en) * 2003-12-11 2006-08-23 Epigenomics AG Method and nucleic acids for the improved treatment of breast cell proliferative disorders
ES2550614T3 (en) * 2004-04-09 2015-11-11 Genomic Health, Inc. Gene expression markers to predict the response to chemotherapy

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108367995A (en) * 2015-10-06 2018-08-03 安大略省癌症研究所 Histone approach is targeted to detect and overcome anthracycline resistant
CN108367995B (en) * 2015-10-06 2021-08-27 安大略省癌症研究所 Targeted histone pathway to detect and overcome anthracycline tolerance

Also Published As

Publication number Publication date
WO2007085497A3 (en) 2007-12-06
WO2007085497A2 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
WO2007085497A3 (en) Markers for the prediction of outcome of anthracycline treatment
WO2004066941A3 (en) Expression profiles for colon cancer and methods of use
WO2007103808A3 (en) Microrna expression profile associated with pancreatic cancer
EP2610347A3 (en) Methods of determining the prognosis of a subject with pancreatic cancer
EP2487257A3 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
WO2006024283A3 (en) Compounds and methods for the treatment, diagnosis and prognosis of pancreatic diseases
WO2006012468A3 (en) Detection of oligonuleotides by dual hybridization
WO2005059108A3 (en) Gene expression profiles and methods of use
WO2008115419A3 (en) Gene expression markers for prediction of patient response to chemotherapy
WO2005113816A3 (en) Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
WO2007058968A3 (en) Gene expression profiles and methods of use
MX2007012782A (en) Methods and nucleic acids for analyses of cellular proliferative disorders.
WO2009103790A3 (en) Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-positive and her2-positive subtypes with clinical implications
SI1730315T1 (en) Polymorphisms in nod2/card15 gene
Buchner et al. Downregulation of HNF-1B in renal cell carcinoma is associated with tumor progression and poor prognosis
WO2005121360A3 (en) Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients
WO2005032495A3 (en) Gene expression profiles and methods of use
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
WO2005083086A3 (en) Epha4 as therapeutic target of prc and pdaca
WO2010007083A3 (en) Methods and nucleic acids for analyses of cell proliferative disorders
WO2010082004A9 (en) Methods for determining the likelihood of a patient contracting a nosocomial infection and for determining the prognosis of the course of a septic syndrome
WO2008008983A3 (en) Methods and nucleic acids for analyses of cellular proliferative disorders
WO2006133866A3 (en) Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients
WO2006108659A3 (en) Gene expression profiles being predictive for the response of tumors to pharmaceutically effective compounds
WO2007003397A3 (en) Method and nucleic acids for the improved treatment of cancers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07703150

Country of ref document: EP

Kind code of ref document: A2